Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02290-y. Online ahead of print.
NO ABSTRACT
PMID:38830959 | DOI:10.1038/s41375-024-02290-y
Recent Content
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML
- (no title)
- Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma